People with obesity who took Eli Lilly's daily oral GLP-1 drug orforglipron lost an average of 12.4% of their body weight, ...

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

Weight loss medications such as Wegovy and Zepbound have garnered an enormous amount of attention recently for their ability to help some users lose significant amounts of weight relatively easily.

Innovent Biologics receives US FDA clearance to initiate phase 1 clinical trial of novel oral GLP-1R agonist, IBI3032: San Francisco Wednesday, August 6, 2025, 14:00 Hrs [IST] Inn ...

Three presentations at ADA 2025 highlighted the therapeutic potential of icovamenib across multiple aspects of metabolic health:In patients with type 2 diabetes (T2D) not achieving glycemic targets, ...

Eris Lifesciences plans to lead in generic semaglutide drugs. The patent for Novo Nordisk's drug expires in India in March ...

SAN FRANCISCO, CA, USA and SUZHOU, China I August 4, 2025 I Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company ...

An older woman with dementia and type 2 diabetes was started on semaglutide and subsequently developed severe psychological and physical symptoms, including apathy, significant weight loss and ...

Learn more about the gut microbiome’s digestion of the amino acid tryptophan, which creates byproducts with potential for ...

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals (NASDAQ: MDGL) announced Monday it has secured exclusive global rights to develop ...

Conshohocken, Pa. Friday, August 1, 2025, 15:00 Hrs [IST] ...

License agreement supports Madrigal's pipeline strategy to develop innovative combination treatments for MASH, anchored by its foundational therapy Rezdiffra (resmetirom) Combining Rezdiffra with the ...